Skip to main content
. 2016 Mar 21;7(15):20999–21012. doi: 10.18632/oncotarget.8236

Figure 6. CXCR4 mediates RUNX2-promoted invasiveness and metastasis of GC cells.

Figure 6

(A) Chemotaxis of GC cells in response to the CXCR4 ligand SDF-1a (CXCL12, 10 nM/L). (B) Silencing CXCR4 or treatment with AMD3100 (50 ng/mL) attenuates the invasion ability of RUNX2-overexpressing SGC7901 cells. (C) Representative images of xenograft tumor section show that tumors formed by SGC7901-exRUNX2-Mock cells, but not SGC7901-exRUNX2-shCXCR4 cells, invade into the submucosa (black dotted line). (D) Representative images show that AMD3100 treatment reduced the invasion ability of RUNX2-overexpressing SGC7901 cells (black dotted line). Mice (n = 5 for each group) were intra-peritoneally injected with AMD3100 (7.5 mg/kg) every 3 days and the tumors were harvested after GC cell orthotopic implantation for 8 weeks. Scale bar = 50 μm. (E and F) Overall survival curves show that mice bearing tumors formed by SGC7901-exRUNX2 cells with CXCR4 knockdown or AMD3100 treatment have a long survival than mice implanted with mock or PBS treated SGC7901-exRUNX2 cells (n = 5 for each group). **P < 0.01, Student's t test.